Biotech Values

[BTH]

CLDX announced that it will have data on CDX-1135 before the end of the year. This was a bit surprising, because the consensus seemed to be that CLDX could not enroll the trial, since Soliris is now being used in DDD

Huh? I was under the impression that (a) the company for the past several conferences has ALWAYS said they would have results by year end in 1135, (b) it is a pilot study of 5 patients (likely all children); the delays have nothing to do with Soliris, and (c) "Soliris is now being used in DDD" ---- don't you mean "being studied in DDD"? I do not recall eculizumab being approved for dense deposit disease.